Vaccine. 2014 Apr 12. pii: S0264-410X(14)00483-6. doi: 10.1016/j.vaccine.2014.03.092. [Epub ahead of print]

Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic mice

Bissati KE¹, Zhou Y², Dasgupta D³, Cobb D⁴, Dubey JP⁵, Burkhard P⁶, Lanar DE³, McLeod R².

 

Abstract

We created and produced a novel self-assembling nanoparticle platform for delivery of peptide epitopes that induces CD8⁺ and CD4⁺T cells that are protective against Toxoplasma gondii infection. These self-assembling polypeptide nanoparticles (SAPNs) are composed of linear peptide (LP) monomers which contain two coiled-coil oligomerization domains, the dense granule 7 (GRA7_20-28 LPQFATAAT) peptide and a universal CD4⁺T cell epitope (derived from PADRE). Purified LPs assemble into nanoparticles with icosahedral symmetry, similar to the capsids of small viruses. These particles were evaluated for their efficacy in eliciting IFN-γ by splenocytes of HLA-B*0702 transgenic mice and for their ability to protect against subsequent T. gondii challenge. This work demonstrates the feasibility of using this platform approach with a CD8⁺ epitope that binds HLA-B7 and tests the biological activity of potentially protective peptides restricted by human major histocompatibility complex (HLA) class I molecules in HLA transgenic mice.
Copyright © 2014 Elsevier Ltd. All rights reserved.

KEYWORDS:

HLA-B7, Nanoparticles, Toxoplasma gondii, Vaccine

PMID:

24736000

[PubMed - as supplied by publisher]